Get the Stockscreener App
3.91
3.69%
-0.15
After Hours:
3.89
-0.02
-0.51%
Atai Beckley N V stock is traded at $3.91, with a volume of 2.37M.
It is down -3.69% in the last 24 hours and down -0.51% over the past month.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.
See More
Previous Close:
$4.06
Open:
$4.09
24h Volume:
2.37M
Relative Volume:
0.44
Market Cap:
$1.42B
Revenue:
$2.59M
Net Income/Loss:
$-137.89M
P/E Ratio:
-4.8272
EPS:
-0.81
Net Cash Flow:
$-69.76M
1W Performance:
-11.54%
1M Performance:
-0.51%
6M Performance:
+67.81%
1Y Performance:
+231.36%
1-Day Range:
$3.88
$4.2106
1-Week Range:
$3.88
$4.63
52-Week Range:
$1.15
$6.75
Atai Beckley N V Stock (ATAI) Company Profile
Name
Atai Beckley N V
Sector
Industry
Phone
49 89 2153 9035
Address
PROF. J.H. BAVINCKLAAN 7, AMSTELVEEN
Compare ATAI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATAI
Atai Beckley N V
|
3.91 | 1.47B | 2.59M | -137.89M | -69.76M | -0.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Atai Beckley N V Stock (ATAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-13-25 | Initiated | Needham | Buy |
| Jul-29-25 | Initiated | Oppenheimer | Outperform |
| Nov-18-24 | Reiterated | H.C. Wainwright | Buy |
| Apr-03-24 | Upgrade | Maxim Group | Hold → Buy |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Nov-30-21 | Initiated | Maxim Group | Buy |
| Nov-11-21 | Initiated | ROTH Capital | Buy |
| Oct-18-21 | Initiated | H.C. Wainwright | Buy |
| Sep-01-21 | Initiated | Jefferies | Buy |
| Jul-13-21 | Initiated | Berenberg | Buy |
| Jul-13-21 | Initiated | Canaccord Genuity | Buy |
| Jul-13-21 | Initiated | Cantor Fitzgerald | Buy |
| Jul-13-21 | Initiated | Citigroup | Buy |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-13-21 | Initiated | Credit Suisse | Outperform |
| Jul-13-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-08-21 | Initiated | Aegis Capital | Buy |
View All
Atai Beckley N V Stock (ATAI) Latest News
Atai Life Sciences N.V. (ATAI) Secures Patent for Social Anxiety Disorder Formulation - Insider Monkey
CapEx per share of Atai Beckley N.V – LSX:A3CSB4 - TradingView — Track All Markets
New EMP-01 Patent Win Could Be A Game Changer For Atai Beckley (ATAI) - simplywall.st
ATAI Beckley Secures US Patent for EMP-01 to Treat Social Anxiety Disorder; Shares Up Pre-Bell - marketscreener.com
AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio - The Manila Times
AtaiBeckley (NASDAQ: ATAI) gains EMP-01 patent, eyes Phase 2a data in 2026 - Stock Titan
Atai Beckley files prospectus supplement for registered shares after Beckley Psytech acquisition - Investing.com Australia
Atai Beckley files prospectus supplement for registered shares after Beckley Psytech acquisition By Investing.com - Investing.com South Africa
ATAI Life Sciences Files Prospectus for Share Registration - TipRanks
Atai Beckley N.V. Files Prospectus Supplement for Common Shares - TradingView — Track All Markets
Atai Life Sciences (ATAI): Assessing an 8.8x Price-to-Book Valuation After a Volatile Share Price Run - Yahoo Finance
Atai Beckley (ATAI) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
ATAIAtai Beckley N.V Short Interest - Finviz
ATAI Life Sciences Files Prospectus for Share Resale - MSN
atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates - ADVFN
Form 8-KCurrent report - ADVFN
AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - ADVFN
[Form 4] Atai Beckley N.V. Insider Trading Activity - Stock Titan
H.C. Wainwright Maintains Buy on Atai Beckley (ATAI) Following Breakthrough Therapy and Merger Completion - MSN
Atai Beckley N.V. (ATAI) latest stock news and headlines - Yahoo Finance UK
AtaiBeckley advances BPL-003 toward Phase 3 After Strong Phase 2 Data topline data i - Proactive financial news
Atai Beckley NV (NASDAQ:ATAI)Shares, Dividends & News - intelligentinvestor.com.au
Enhanced (ATAI) overhauls leadership, appoints new CEO, executive chairman and CFO - Stock Titan
Atai Beckley N.V. (ATAI) Receives Buy Rating on BPL-003 Edge against Spravato - MSN
Atai Beckley N.V (ATAI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
H.C. Wainwright reiterates Buy rating on atai Life Sciences stock By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Buy rating on atai Life Sciences stock - Investing.com India
AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London - The Manila Times
AtaiBeckley (NASDAQ: ATAI) London fireside chat at 11:30 GMT; replay for 90 days - Stock Titan
AtaiBeckley advances clinical pipeline, strengthens balance sheet in Q3 - Proactive financial news
Atai Beckley Q3 Loss Widens, Revenue Rises; Shares Down Pre-Bell - MarketScreener
[8-K] ATAI Life Sciences N.V. Reports Material Event | ATAI SEC FilingForm 8-K - Stock Titan
Atai Beckley N.V. Announces Breakthrough Therapy Designation for BPL-003 and Positive Phase 2 Results for Treatment-Resistant Depression - Quiver Quantitative
Earnings Flash (ATAI) Atai Beckley N.V. Reports Q3 Revenue $749,000 - MarketScreener
Earnings Flash (ATAI) Atai Beckley Posts Q3 Net Loss $0.28 a Share, vs. FactSet Est of $0.11 Loss - MarketScreener
AtaiBeckley (NASDAQ: ATAI) closes approx. $150M offering, funding into 2029 - Stock Titan
AtaiBeckley’s BPL-003 could redefine psychedelics dosing, analysts believe - Proactive Investors
Atai Beckley N.V. (ATAI) Discusses BPL-003 Phase IIb Open-Label Extension Study Results in Treatment Resistant DepressionSlideshow (NASDAQ:ATAI) 2025-11-10 - Seeking Alpha
Atai Beckley Reports Positive Phase 2b Extension Data for Depression Treatment - MarketScreener
Why Atai Life Sciences N.V. (9VC) stock stays undervalued2025 Earnings Impact & Precise Swing Trade Alerts - newser.com
Why Atai Life Sciences N.V. (9VC) stock appears on watchlistsPortfolio Performance Report & Low Drawdown Investment Strategies - newser.com
AtaiBeckley Announces Positive Topline Data from the Phase - GlobeNewswire
Why Atai Life Sciences N.V. (9VC) stock is trending on social media2025 EndofYear Setup & Intraday High Probability Alerts - newser.com
Will Atai Life Sciences N.V. (9VC) stock justify high valuationWeekly Gains Report & Fast Exit Strategy with Risk Control - newser.com
Is Atai Life Sciences N.V. stock poised for growth2025 Earnings Impact & Weekly Market Pulse Updates - newser.com
Is Atai Life Sciences N.V. (9VC) stock nearing a technical breakoutJuly 2025 Macro Moves & Daily Growth Stock Tips - newser.com
Will Atai Life Sciences N.V. stock reach all time highs in 2025Trade Ideas & Safe Capital Preservation Plans - newser.com
ATAI BECKLEY NV Insider Trades - Nasdaq
Atai Beckley N V Stock (ATAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.31%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):